Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Cyclerion Therapeutics Inc
CYCN | US
1.49
USD0.08
5.67%
CYCN | US
About Cyclerion Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
09/03/2026
Close
1.49
Open
1.38
High
1.49
Low
1.33
Cyclerion Therapeutics Inc. a clinical-stage biopharmaceutical company engages in the discovering development and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is Zagociguat (CY6463) a CNS-penetrant soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy lactic acidosis and stroke-like episodes as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat an orally administered systemic sGC stimulator which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 a CNS-targeted sGC stimulator that is in preclinical trial for the treatment of neuropsychiatric diseases and disorders. It has license agreement with Akebia Therapeutics Inc. for the development manufacture medical affairs and commercialization of pharmaceutical products including pharmaceutical compound and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge Massachusetts.
View LessCYCN | US
Risk
50.0
Sharpe
-0.49
Luna's Score
49/100
Recommendation
Hold
Luna says (CYCN | US)
What's Working
Strength based on increasing price with high volume
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
43.5%1 month
50.0%3 months
118.8%6 months
110.3%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.69
Debt to equity
-
Debt to assets
-
Ent. to EBITDA
0.56
Ent. to rev.
0.52
PEG
-
Other Fundamentals
EBITDA
-9.58M
MarketCap
3.75M
MarketCap(USD)
3.75M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
14.10
Ret. on equity
-150.25
Short ratio
2.56
Short perc.
0.65
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.32
Range1M
0.47
Range3M
1.25
Volumes: Market Activity
Rel. volume
1.25
Price X volume
81.25K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.56 | 0.53 | Par |
| Ent. to Revenue | 0.52 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.69 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 118.82 | 72.80 | Riskier |
| Debt to Equity | - | -1.23 | - |
| Debt to Assets | - | 0.25 | - |
| Market Cap | 3.75M | 3.66B | Emerging |
